info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Global Multiplex Assays Market worth $6.47 billion by 2030

Global Multiplex Assays Market worth $6.47 billion by 2030


Published Date: Mar-2022 | Report Format:Electronic (PDF)

The report” Multiplex Assays” Market by Products & Services (Instruments, Consumables, and Software and Services), Type (Nucleic Acid Multiplex Assays, Protein Multiplex Assays, and Cell-Based Multiplex Assays), Technology (Fluorescence Detection, Luminescence, Flow Cytometry, Multiplex Real-Time PCR, and Others), Applications (Research & Development, and Clinical Diagnostics), End-User (Hospitals & Research Institutes, Pharmaceutical & Biotechnology Companies, Reference Laboratories, and others) - Global Forecast to 2030. "The Multiplex Assays Market worldwide is expected to reach USD 6.47 billion by 2030 from USD 3.13 billion in 2020, at a CAGR of 7.53% over the forecasted period. The continuous rising prevalence of infectious and chronic (non-communicable) diseases across the globe, the rising prevalence of multiplex assays in companion diagnostics, the rising awareness of disease diagnosis, and the rise in the requirement for effective analytical platforms in R&D. are some of the pivotal factors driving the growth of this market significantly.

To know more about the report, Click on the link https://www.strategicmarketresearch.com/market-report/multiplex-assays-market

 

By Products & Services, the ‘Consumables’ segment dominated the market significantly in 2020

Based on Products & Services, the Multiplex Assays industry worldwide has been broadly fragmented into Instruments, Consumables, and Software and Services. The 'Consumables' segment held the highest share of almost 44.27% of the entire market in 2020. It also held the fastest growth with a steady CAGR throughout the forecasted period. The vital factors like the increase in the number of recurring purchases of assays worldwide, and higher usage of reagents for facilitating research applications on consumables are fuelling the growth of this segment.

 

By Type, the ‘Protein Multiplex Assays’ segment held the largest market share significantly in 2020

Based on Type, the Multiplex Assays industry worldwide has been broadly fragmented into Nucleic Acid Multiplex Assays, Protein Multiplex Assays, and Cell-Based Multiplex Assays. The ‘Protein Multiplex Assays’ segment dominated the overall market with a steady CAGR throughout the estimated period because of the sheer focus on proteomics studies for clinical diagnostics and biomarker researches. As per IBISWorld, in 2021, there will be around 28,393 Diagnostic & Medical Laboratory businesses in the USA, with an increase of up to 1.5 percent from 2020.

 

By Technology, the ‘Flow Cytometry’ segment dominated the market significantly in 2020

Based on Technology, the Multiplex Assays industry worldwide has been broadly fragmented into Fluorescence Detection, Luminescence, Flow Cytometry, Multiplex Real-Time PCR, and Others The ' Flow Cytometry ' segment held the largest share (about 37.28%) of the entire market in 2020 with a steady CAGR of 8.27%. The factors such as the wide range of flow cytometry applications in the detection and measurement of RNA, protein expression, cell viability & toxicity, including the identification and characterization of various cell types are fuelling the overall market growth.

 

By Applications, the ‘Research & Development’ segment dominated the market significantly in 2020

Based on Applications, the Multiplex Assays industry has been segmented into Research & Development, and Clinical Diagnostics. The 'Research & Development' segment dominated the market in 2020 due to the raise of funds by governments worldwide on the broad applications of multiplex assay technologies in R&D functions. The R&D outsourcing services market is progressing at a CAGR of 7.93%, which in turn is propelling the overall growth of this segment.

 

By End-User, the ‘Pharmaceutical & Biotechnology Companies’ segment held the largest market share in 2020

Based on End-User, the Multiplex Assays industry worldwide has been bifurcated into Hospitals & Research Institutes, Pharmaceutical & Biotechnology Companies, Reference Laboratories, and Others. The 'Pharmaceutical & Biotechnology Companies' accounted for the highest market share in 2020. Factors such as the increase in the number of adoptions of multiplex assays in the field of drug discovery by pharmaceuticals, and the rising focus of biotechnological companies on developing monoclonal and biosimilars antibodies are significantly driving the overall growth of this segment.

 

North America held the most regional share of the market with a CAGR of 8.93% in 2020, followed by Europe. The highest share of the North American region is due to the presence of leading pharmaceutical and biotechnology companies, increased R&D expenditures by the government, and the presence of established pharmaceutical industries. In the USA, the Multiplex Assays Market is significantly higher than any other country around the world. In addition, the government expenditure for the clinical services laboratory has increased by up to 5.23% between 2010 to 2020, which has highly augmented the Multiplex Assays Market in the United States.

 

The major vendors in the Global Multiplex Assays Market include Luminex Corporation, Illumina Inc, Bio-Rad Laboratories, Inc, Qiagen N.V., Thermo Fisher Scientific Inc, Abcam plc, Merck KGaA, Agilent Technologies, Inc, Becton, Dickinson and Company, Randox Laboratories, Quanterix, Bio-Techne Corporation, Olink, DiaSorin S.p.A., Seegene, Promega Corporation, Meso Scale Diagnostics, Siemens Healthineers, PerkinElmer Inc, Antigenix America, Inc, Enzo Life Sciences, Inc, Shimadzu Biotech, Boster Biological Technology, AYOXXA Biosystems GmbH, and Cayman Chemical Company. 

 

Recent Developments: -

  • On August 25th, 2021, Becton, Dickinson, and Company launched its automated high-throughput diagnostic BD COR System. The system efficiently uses sample management software algorithms and robotics technology to set up a new level of standard in molecular testing automation for the variety of infectious diseases in core laboratories in the USA.
  • On April 20th, 2021, Illumina successfully acquired GRAIL, one of the world’s most well-known healthcare companies focused on providing early life-saving detection of multiple types of cancers. However, at the time of the European Commission's ongoing regulatory review, Illumina will hold GRAIL as a separate company. 
  • On February 26th, 2021, Thermo Fisher Scientific succeeded in acquiring Mesa Biotech, which is a privately held POC (point-of-care) molecular diagnostic company. By the combination of Thermo Fisher's excellence in operations, existing sales and distribution channels with Mesa's innovative platform, and direct access to the raw materials, rapid scaling of manufacturing volume can be performed with ease.

Choose License Type



$0
$0
$0
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved